Loading…
Huons BioPharma signed a deal potentially worth 97.2 billion won ($83.4 million) with Germany's Haemato Pharm to supply its Hutox botulinum toxin for sale in 29 European countries. The deal includes clinical trials in Europe, with marketing expected to begin in 2025.